# Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

> **NCT02605122** · PHASE2,PHASE3 · TERMINATED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Community-acquired Bacterial Pneumonia

## Interventions

- **DRUG:** Solithromycin
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT02605122
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2018-03-21
- **Final completion:** 2018-03-21
- **Target enrollment:** 97 (ACTUAL)
- **Why stopped:** Development not proceeding
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605122, "Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02605122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*